Zai Lab Limited, a Shanghai-based biopharmaceutical company, announced the Hong Kong Department of Health has approved Zejula (niraparib), an oral, once-daily poly polymerase inhibitor in Hong Kong for adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian cancer who are in a complete response or partial response to platinum-based chemotherapy.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
